Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Fold Holdings (NasdaqCM:FLD) with a Buy ...

Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Alto Neuroscience (NYSE:ANRO) with a Buy ...

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.79, a high ...

H.C. Wainwright lowered the firm’s price target on Bicara Therapeutics (BCAX) to $44 from $45 and keeps a Buy rating on the shares following ...

H.C. Wainwright analyst Scott Buck lowered the firm’s price target on Knightscope (KSCP) to $12 from $16 and keeps a Buy rating on the shares.

Surf Air Mobility Inc. (NYSE: SRFM) (the "Company"), a leading regional air mobility platform, closed on the previously announced purchase and sale of 2,000,000 shares of common stock (or pre-funded ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on Benitec BioPharma (NASDAQ:BNTC) shares, maintaining a $28.00 price target. The stock has shown remarkable momentum, delivering a 225% return over ...